Aktienanalyse zu Nuvation Bio Inc (NUVB)NUVBNuvation Bio Inc

Nuvation Bio Inc. is a global oncology company. The Company is focused on tackling cancer treatment. Its diverse pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor, and a drug-drug conjugate (DDC) program. IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), which is detected in various tumors, including gliomas. Its platform leverages its drug discovery and chemistry expertise to find the minimum target binding sites of drug X and drug Y and fuse them together, while maintaining activity. Its DDCs are designed to selectively bind to intracellular as well as surface cell membrane targets that are expressed more highly in specific target tissues and to potently deliver anti-cancer warheads to these target tissues. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nuvation Bio Inc is a good buy right now due to its recent FDA approval for IBTROZI, which enhances its long-term growth potential, and the analyst consensus price target of $13.36 suggests a potential upside of 137.76% from the current price of $4.45. However, the stock has a low RSI of 16.317, indicating it is oversold, and the company reported a net income loss of $62.84 million in Q2 2026, which is a significant risk.